JG

James Garner

Percheron Therapeutics Limited | Chief Executive Officer, Managing Director
Dr Garner brings experience in drug development and commercialization, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included phase I-IV clinical trials, product registration, reimbursement, and business development. Most recently James served as CEO of Kazia Therapeutics Limited (NASDAQ:KZIA), a clinical stage, oncology-focused company where James rebuilt the organization around a pipeline of novel assets and financing via capital markets and non-dilutive opportunities.

Company and Roles

Company
Title
Tenure
Since
PER
PER
Percheron Therapeutics Limited
  • Chief Executive Officer
  • Managing Director
3yrs, 2mthMay 2023

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
PER
PER
Percheron Therapeutics Limited
15/04/2674,900,000N/A25,390,000N/A
ANP
ANP
29/11/231,000,000N/A6,690,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
PER
PER
Percheron Therapeutics Limited
15/04/26
Issued
21,400,000$0.005$107,000Rights issue
PER
PER
Percheron Therapeutics Limited
15/04/26
Issued
10,700,000$0.004$42,800Rights issue
PER
PER
Percheron Therapeutics Limited
19/12/25
Buy
1,000,000$0.009$8,500On-market trade
PER
PER
Percheron Therapeutics Limited
30/06/25
Buy
2,500,000$0.010$24,960On-market trade
PER
PER
Percheron Therapeutics Limited
20/05/25
Issued
5,000,000$0.035$175,000Issue of options